The Role of Folate-supplementation in Depression: A Narrative Review

Author(s): Joshua Falade*, Adejoke Y. Onaolapo, Olakunle J. Onaolapo

Journal Name: Current Psychopharmacology

Volume 10 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: There is a relationship between the etiology and management of clinical depression and vitamin deficiencies.

Aim: To review the effect of dietary folic acid supplementation on cause, severity and treatment of depression.

Methods: A narrative review of empirical and theoretical literature on the effect of folic acid supplementation on the severity and treatment outcomes of depression.

Results: Many enzymes and neurotransmitters depend on folic acid for optimal functions. The monoamine hypothesis of depression confirms the depletion of serotonin, dopamine, and norepinephrine. The systemic level of methyl folate is dependent upon the enzyme methylenetetrahydrofolate reductase [MTHFR], which is encoded by a polymorphic gene [C677T-MTHFR], as well as being dependent on dietary folic acid intake. However, folate has procarcinogenic properties because its coenzymes are involved in de novo purine and thymine nucleotide biosynthesis. Besides, folate deficiency in normal tissues may also predispose to neoplastic transformation, while folate supplementation may suppress the development of tumors in normal tissues. Epidemiological studies revealed that low folate status is associated with depression; especially in terms of severity and the outcome of antidepressant use.

Conclusion: The role of folic acid in the etiology and the management of depression cannot be overemphasized. Folate supplementation has been yielding positive results in the management of depression.

Keywords: Folic acid, depression, neurotransmitters, dietary supplementation, review, enzymes.

[1]
Friedrich MJ. Depression is the leading cause of disability around the world. JAMA 2017; 317(15): 1517.
[http://dx.doi.org/10.1001/jama.2017.3826] [PMID: 28418490]
[2]
Fried EI, Epskamp S, Nesse RM, Tuerlinckx F, Borsboom D. What are ‘good’ depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. J Affect Disord 2016; 189: 314-20.
[http://dx.doi.org/10.1016/j.jad.2015.09.005] [PMID: 26458184]
[3]
Barry LC, Coman E, Wakefield D, Trestman RL, Conwell Y, Steffens DC. Functional disability, depression, and suicidal ideation in older prisoners. J Affect Disord 2020; 266: 366-73.
[http://dx.doi.org/10.1016/j.jad.2020.01.156] [PMID: 32056900]
[4]
Johnson AM. Music therapy: an adjunct treatment option for treating depression in geriatric patients. 2019. Available at: https://repository.arizona.edu/handle/10150/636566
[5]
Alloush M, Bloem JR. Neighborhood violence, poverty, and psychological well-being 2020. Available at: https://arefiles.ucdavis.edu/uploads/filer_public/1a/30/1a300656-db08-46ec-a81d-b9e7cc8bab69/alloush_violencesouthafrica.pdf
[6]
Patel V. Alcohol use and mental health in developing countries. Ann Epidemiol 2007; 17(5): S87-92.
[http://dx.doi.org/10.1016/j.annepidem.2007.01.019]
[7]
Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health 2007; 61(7): 631-7.
[http://dx.doi.org/10.1136/jech.2006.050385] [PMID: 17568057]
[8]
Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition [Burbank, Los Angeles County, Calif] 2000; 16(7-8): 544-6.
[http://dx.doi.org/10.1016/S0899-9007(00)00327-0]
[9]
Bottiglieri T. Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(7): 1103-12.
[http://dx.doi.org/10.1016/j.pnpbp.2005.06.021] [PMID: 16109454]
[10]
Petridou ET, Kousoulis AA, Michelakos T, et al. Folate and B12 serum levels in association with depression in the aged: a systematic review and meta-analysis. Aging Ment Health 2016; 20(9): 965-73.
[http://dx.doi.org/10.1080/13607863.2015.1049115] [PMID: 26055921]
[11]
Shakur YA, Garriguet D, Corey P, O’Connor DL. Folic acid fortification above mandated levels results in a low prevalence of folate inadequacy among Canadians. Am J Clin Nutr 2010; 92(4): 818-25.
[http://dx.doi.org/10.3945/ajcn.2010.29696] [PMID: 20739423]
[12]
Chan Y-M, Bailey R, O’Connor DL. Folate. Adv Nutr 2013; 4(1): 123-5.
[http://dx.doi.org/10.3945/an.112.003392] [PMID: 23319130]
[13]
Sarris J, Murphy J, Mischoulon D, et al. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Focus Am Psychiatr Publ 2018; 16(3): 328-40.
[http://dx.doi.org/10.1176/appi.focus.16304] [PMID: 32015713]
[14]
Empty C. Nootropic vitamins and minerals-essential nutrients for optimal brain health and cognitive function. Brain 2018. Available at: https://www.mindlabpro.com/blogs/nootropics/nootropic-vitamins-minerals
[15]
Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers 2016; 2(1): 16065.
[http://dx.doi.org/10.1038/nrdp.2016.65] [PMID: 27629598]
[16]
Young RC, Kiosses D, Heo M, et al. Age and ratings of manic psychopathology. Bipolar Disord 2007; 9(3): 301-4.
[http://dx.doi.org/10.1111/j.1399-5618.2007.00393.x] [PMID: 17430306]
[17]
Durisko Z, Mulsant BH, Andrews PW. An adaptationist perspective on the etiology of depression. J Affect Disord 2015; 172: 315-23.
[http://dx.doi.org/10.1016/j.jad.2014.09.032] [PMID: 25451432]
[18]
Avenevoli S, Swendsen J, He J-P, Burstein M, Merikangas KR. Major depression in the national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment. J Am Acad Child Adolescent Psych 2015; 54(1): 37-44.
[19]
Okereke OI, Cook NR, Albert CM, Van Denburgh M, Buring JE, Manson JE. Effect of long-term supplementation with folic acid and B vitamins on risk of depression in older women. Br J Psychiatry 2015; 206(4): 324-31.
[http://dx.doi.org/10.1192/bjp.bp.114.148361] [PMID: 25573400]
[20]
Ferrari F, Villa RF. The neurobiology of depression: an integrated overview from biological theories to clinical evidence. Mol Neurobiol 2017; 54(7): 4847-65.
[http://dx.doi.org/10.1007/s12035-016-0032-y] [PMID: 27510505]
[21]
Danese A, Moffitt TE, Harrington H, et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch Pediatr Adolesc Med 2009; 163(12): 1135-43.
[http://dx.doi.org/10.1001/archpediatrics.2009.214] [PMID: 19996051]
[22]
Brown GW, Harris TO, Craig TKJ. Exploration of the influence of insecure attachment and parental maltreatment on the incidence and course of adult clinical depression. Psychol Med 2019; 49(6): 1025-32.
[http://dx.doi.org/10.1017/S0033291718001721] [PMID: 30107862]
[23]
Nanthakumar S, Bucks RS, Skinner TC. Are we overestimating the prevalence of depression in chronic illness using questionnaires? Meta-analytic evidence in obstructive sleep apnoea. Health Psychol 2016; 35(5): 423-32.
[http://dx.doi.org/10.1037/hea0000280] [PMID: 26523355]
[24]
Won MS, Kim S, Yang YJ. Comparison of health status and nutrient intake between depressed women and non-depressed women: based on the 2013 Korea National Health and Nutrition Examination Survey. Clin Nutr Res 2016; 5(2): 112-25.
[http://dx.doi.org/10.7762/cnr.2016.5.2.112] [PMID: 27152301]
[25]
Pasco JA, Jacka FN, Williams LJ, et al. Dietary selenium and major depression: a nested case-control study. Complement Ther Med 2012; 20(3): 119-23.
[http://dx.doi.org/10.1016/j.ctim.2011.12.008] [PMID: 22500660]
[26]
Lakhan SE, Vieira KF. Nutritional therapies for mental disorders. Nutr J 2008; 7(1): 2.
[http://dx.doi.org/10.1186/1475-2891-7-2] [PMID: 18208598]
[27]
Styczeń K, Sowa-Kućma M, Siwek M, et al. The serum zinc concentration as a potential biological marker in patients with major depressive disorder. Metab Brain Dis 2017; 32(1): 97-103.
[http://dx.doi.org/10.1007/s11011-016-9888-9] [PMID: 27502410]
[28]
Khosravi M, Hosseinzadeh M, Golzar M, Majdzadeh R, Sotoudeh G. Comparison between Macro & Micro Nutrient Intake in Depressed Patients with Healthy People. J Nutr Food Sec 2019; 4(2): 83-92.
[http://dx.doi.org/10.18502/jnfs.v4i2.769]
[29]
Hiraoka M, Kagawa Y. Genetic polymorphisms and folate status. Congenit Anom (Kyoto) 2017; 57(5): 142-9.
[http://dx.doi.org/10.1111/cga.12232] [PMID: 28598562]
[30]
Mulinari S. Explaining biological depression theories. Philos Psychiatry Psychol 2018; 25(4): 309-10.
[http://dx.doi.org/10.1353/ppp.2018.0043]
[31]
Juruena MF, Bocharova M, Agustini B, Young AH. Atypical depression and non-atypical depression: Is HPA axis function a biomarker? A systematic review. J Affect Disord 2018; 233: 45-67.
[http://dx.doi.org/10.1016/j.jad.2017.09.052] [PMID: 29150144]
[32]
Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994; 51(11): 865-74.
[http://dx.doi.org/10.1001/archpsyc.1994.03950110025005] [PMID: 7944875]
[33]
Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000; 61(Suppl. 6): 4-6.
[PMID: 10775017]
[34]
Blackburn TP. Depressive disorders: Treatment failures and poor prognosis over the last 50 years. Pharmacol Res Perspect 2019; 7(3): e00472.
[http://dx.doi.org/10.1002/prp2.472] [PMID: 31065377]
[35]
Norman TR. Multi-modal pharmacological treatments for major depressive disorder: testing the hypothesis. Sharjah: Frontiers in Clinical Drug Research-Central Nervous System 2016; p. 203.
[36]
Küçükibrahimoğlu E, Saygin MZ, Calişkan M, Kaplan OK, Ünsal C, Gören MZ. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol 2009; 65(6): 571-7.
[http://dx.doi.org/10.1007/s00228-009-0650-7] [PMID: 19373461]
[37]
Block W, Träber F, von Widdern O, et al. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol 2009; 12(3): 415-22.
[http://dx.doi.org/10.1017/S1461145708009516] [PMID: 18845018]
[38]
Garakani A, Martinez JM, Yehuda R, Gorman JM. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment. J Affect Disord 2013; 146(2): 262-5.
[http://dx.doi.org/10.1016/j.jad.2012.06.037] [PMID: 22840611]
[39]
Chandley MJ, Szebeni A, Szebeni K, et al. Elevated gene expression of glutamate receptors in noradrenergic neurons from the locus coeruleus in major depression. Int J Neuropsychopharmacol 2014; 17(10): 1569-78.
[http://dx.doi.org/10.1017/S1461145714000662] [PMID: 24925192]
[40]
Karolewicz B, Stockmeier CA, Ordway GA. Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology 2005; 30(8): 1557-67.
[http://dx.doi.org/10.1038/sj.npp.1300781] [PMID: 15920498]
[41]
Berk M, Plein H, Ferreira D. Platelet glutamate receptor supersensitivity in major depressive disorder. Clin Neuropharmacol 2001; 24(3): 129-32.
[http://dx.doi.org/10.1097/00002826-200105000-00002] [PMID: 11391122]
[42]
Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015; 23(1): 1-21.
[http://dx.doi.org/10.1037/a0038550] [PMID: 25643025]
[43]
Xu J, Wang R, Liu Y, Liu D, Jiang H, Pan F. FKBP5 and specific microRNAs via glucocorticoid receptor in the basolateral amygdala involved in the susceptibility to depressive disorder in early adolescent stressed rats. J Psychiatr Res 2017; 95: 102-13.
[http://dx.doi.org/10.1016/j.jpsychires.2017.08.010] [PMID: 28826069]
[44]
Carroll BJ, Cassidy F, Naftolowitz D, et al. Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand Suppl 2007; 115(433): 90-103.
[http://dx.doi.org/10.1111/j.1600-0447.2007.00967.x] [PMID: 17280575]
[45]
Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005; 66(Suppl. 7): 5-13.
[PMID: 16124836]
[46]
Strain J, Hughes C, Pentieva K, Ward M, Hoey L, McNulty H. The B-Vitamins Sustainable Nutrition in a Changing World. Heidelberg: Springer 2017; pp. 185-203.
[http://dx.doi.org/10.1007/978-3-319-55942-1_12]
[47]
Liew S-C. Folic acid and diseases - supplement it or not? Rev Assoc Med Bras (1992) 2016; 62(1): 90-100.
[http://dx.doi.org/10.1590/1806-9282.62.01.90] [PMID: 27008500]
[48]
Araghi SO, Jong JCK-D, van Dijk SC, et al. Folic acid and vitamin B12 supplementation and the risk of cancer: long-term follow-up of the B vitamins for the prevention of osteoporotic fractures [B-PROOF] trial. Cancer Epidemiol Biomarkers Prev 2019; 28(2): 275-82.
[http://dx.doi.org/10.1158/1055-9965.EPI-17-1198] [PMID: 30341095]
[49]
Qin X, Cui Y, Shen L, et al. Folic acid supplementation and cancer risk: a meta-analysis of randomized controlled trials. Int J Cancer 2013; 133(5): 1033-41.
[http://dx.doi.org/10.1002/ijc.28038] [PMID: 23338728]
[50]
Kim Y-I. Folic acid supplementation and cancer risk: point. Cancer Epidemiol Biomarkers Prev 2008; 17(9): 2220-5.
[http://dx.doi.org/10.1158/1055-9965.EPI-07-2557] [PMID: 18768486]
[51]
Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res 2007; 51(3): 267-92.
[http://dx.doi.org/10.1002/mnfr.200600191] [PMID: 17295418]
[52]
Barnett H, D’Cunha NM, Georgousopoulou EN, et al. Effect of folate supplementation on inflammatory markers in individuals susceptible to depression: a systematic review. Exploratory Research and Hypothesis in Medicine 2017; 2(4): 86-100.
[http://dx.doi.org/10.14218/ERHM.2017.00025]
[53]
Marcus MM, Björkholm C, Malmerfelt A, et al. Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study. Eur Neuropsychopharmacol 2016; 26(9): 1401-11.
[http://dx.doi.org/10.1016/j.euroneuro.2016.07.004] [PMID: 27474687]
[54]
McGarel C, Pentieva K, Strain JJ, McNulty H. Emerging roles for folate and related B-vitamins in brain health across the lifecycle. Proc Nutr Soc 2015; 74(1): 46-55.
[http://dx.doi.org/10.1017/S0029665114001554] [PMID: 25371067]
[55]
Ramaekers VT, Sequeira JM, Quadros EV. The basis for folinic acid treatment in neuro-psychiatric disorders. Biochimie 2016; 126: 79-90.
[http://dx.doi.org/10.1016/j.biochi.2016.04.005] [PMID: 27068282]
[56]
Réus GZ, Maciel AL, Abelaira HM, et al. ω-3 and folic acid act against depressive-like behavior and oxidative damage in the brain of rats subjected to early- or late-life stress. Nutrition 2018; 53: 120-33.
[http://dx.doi.org/10.1016/j.nut.2018.03.006] [PMID: 29783176]
[57]
Williams E, Stewart-Knox B, Bradbury I, et al. Effect of folic acid supplementation on mood and serotonin response in healthy males. Br J Nutr 2005; 94(4): 602-8.
[http://dx.doi.org/10.1079/BJN20051501] [PMID: 16197587]
[58]
Mujcic R, J Oswald A. Evolution of well-being and happiness after increases in consumption of fruit and vegetables. Am J Public Health 2016; 106(8): 1504-10.
[http://dx.doi.org/10.2105/AJPH.2016.303260] [PMID: 27400354]
[59]
Young SN. Folate and depression-a neglected problem. J Psychiatry Neurosci 2007; 32(2): 80-2.
[PMID: 17353937]
[60]
Kaur B, Kaur Mal H. Association between malnutrition and depression among elderly of selected rural area of district Faridkot, Punjab. Int J Community Health Med Res 2017; 3(1): 41-5.
[61]
Bender A, Hagan KE, Kingston N. The association of folate and depression: A meta-analysis. J Psychiatr Res 2017; 95: 9-18.
[http://dx.doi.org/10.1016/j.jpsychires.2017.07.019] [PMID: 28759846]
[62]
Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev 2016; 10: CD011286.
[http://dx.doi.org/10.1002/14651858.CD011286.pub2] [PMID: 27727432]
[63]
Lewis SJ, Lawlor DA, Davey Smith G, et al. The thermolabile variant of MTHFR is associated with depression in the British Women’s Heart and Health Study and a meta-analysis. Mol Psychiatry 2006; 11(4): 352-60.
[http://dx.doi.org/10.1038/sj.mp.4001790] [PMID: 16402130]
[64]
Coppen A, Swade C. 5-HT, and depression: the present. In: Briley M, Fillion G, Eds. New concepts in depression. Heidelberg: Springer 2017; p. 120.
[65]
Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005; 19(1): 59-65.
[http://dx.doi.org/10.1177/0269881105048899] [PMID: 15671130]
[66]
Gao L, Liu X, Yu L, Wu J, Xu M, Liu Y. Folic acid exerts antidepressant effects by upregulating brain-derived neurotrophic factor and glutamate receptor 1 expression in brain. Neuroreport 2017; 28(16): 1078-84.
[http://dx.doi.org/10.1097/WNR.0000000000000887] [PMID: 28906345]
[67]
Tolmunen T, Hintikka J, Voutilainen S, et al. Association between depressive symptoms and serum concentrations of homocysteine in men: a population study. Am J Clin Nutr 2004; 80(6): 1574-8.
[http://dx.doi.org/10.1093/ajcn/80.6.1574] [PMID: 15585771]
[68]
Wade RL, Kindermann SL, Hou Q, Thase ME. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy. J Manag Care Pharm 2014; 20(1): 76-85.
[http://dx.doi.org/10.18553/jmcp.2014.20.1.76] [PMID: 24372461]
[69]
Cianciulli A, Salvatore R, Porro C, Trotta T, Panaro MA. Folic acid can polarize the inflammatory response in LPS activated microglia by regulating multiple signaling pathways. Mediators of inflammation 2016; 2016: 5240127.
[70]
Thomas J, Khanam R, Vohora D. Augmentation of effect of venlafaxine by folic acid in behavioral paradigms of depression in mice: Evidence of serotonergic and pro-inflammatory cytokine pathways. Pharmacol Rep 2016; 68(2): 396-403.
[http://dx.doi.org/10.1016/j.pharep.2015.10.003] [PMID: 26922545]
[71]
Almeida OP, Ford AH, Flicker L. Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. Int Psychogeriatr 2015; 27(5): 727-37.
[http://dx.doi.org/10.1017/S1041610215000046] [PMID: 25644193]
[72]
Reynolds E, Crellin R, Bottiglieri T, Laundy M, Toone B, Carney M. Methylfolate as monotherapy in depression. A pilot randomized controlled trial. J Neurol Psychol 2015; 3(1): 5.
[73]
Sepehrmanesh Z, Omidi A, Gholampoor N. Acid folic supplementation in major depressive disorder treatment: A double-blind randomized clinical trial. Iranian Red Crescent Med J 2017; 19(2) 10.5812/ircmj.33243.
[74]
de Koning EJ, van der Zwaluw NL, van Wijngaarden JP, et al. Effects of two-year vitamin B12 and folic acid supplementation on depressive symptoms and quality of life in older adults with elevated homocysteine concentrations: additional results from the B-PROOF study, an RCT. Nutrients 2016; 8(11): 748.
[http://dx.doi.org/10.3390/nu8110748] [PMID: 27886078]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 2
Year: 2021
Published on: 07 December, 2020
Page: [115 - 122]
Pages: 8
DOI: 10.2174/2211556009666201207233954
Price: $65

Article Metrics

PDF: 491
HTML: 2